GABAergic神经元系的发展确定了在扩散半球质瘤,H3G34突变患者中临床可行的点
Ilon Liu1, Gustavo Alencastro Veiga Cruzeiro2, Lynn Bjerke3
1Department of Pediatric Oncology, Dana-Farber Boston Children's Cancer and Blood Disorders Center, Boston, MA 02215, USA; Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA; Department of Neurology with Experimental Neurology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin und Humboldt-Universität zu Berlin, 10117 Berlin, Germany; Berlin Institute of Health at Charité - Universitätsmedizin Berlin, BIH Biomedical Innovation Academy, BIH Charité Digital Clinician Scientist Program, 10117 Berlin, Germany.
扩散半球质瘤 (DHG-H3G34) 是一种具有攻击性的脑瘤. 向CDK6通过将瘤细胞转移到成熟状态,减少生长和改善临床前模型和患者病例的生存率,显示出有希望.
科学领域:
- 神经瘤学神经瘤学
- 发育神经科学的发展神经科学.
- 癌症生物学 癌症生物学
背景情况:
- 扩散半球结质瘤,H3G34R/V-突变 (DHG-H3G34),是没有向治疗的侵袭性儿科脑瘤.
- 这些瘤起源于内部神经元前体,这表明发育途径可能含有治疗线索.
研究的目的:
- 调查DHG-H3G34的发育起源,以确定新的治疗漏洞.
- 探索在DHG-H3G34.3中准细胞循环调节者的潜力.
主要方法:
- 在内部神经元血统发展中划分细胞层次的划定.
- 在DHG-H3G34模型中进行全基因组CRISPR-Cas9查.
- 在体外和体内评估CDK4/6抑制剂和CDK6降解剂的疗效.
- 对患者瘤样本和治疗反应的分析.
主要成果:
- DHG-H3G34瘤表现出空间模式,反映出正在发展的内部神经元原始流.
- 克里斯普尔选鉴定了在内部神经元原生体上调节的基因,作为DHG-H3G34.34的关键依赖.
- CDK6被确定为一个关键的漏洞;DHG-H3G34细胞对CDK4/6抑制剂和CDK6降解剂敏感.
- 在异种移植模型中,治疗诱导了向成熟的内部神经元类状态的转变,减少了瘤生长,并延长了存活时间.
- 一名患有进展性DHG-H3G34的患者在使用CDK4/6抑制剂时经历了17个月的稳定疾病.
结论:
- 类似神经元外原体的状态在DHG-H3G34.4中具有明显的脆弱性.
- CDK6是对DHG-H3G34.34的有希望的,临床可行的治疗标.
- 向CDK6提供了一种潜在的策略,可以诱导分化和控制瘤进展.
更多相关视频
06:32Evaluation of Biomarkers in Glioma by Immunohistochemistry on Paraffin-Embedded 3D Glioma Neurosphere Cultures
Published on: January 9, 2019
07:39Co-culture of Glutamatergic Neurons and Pediatric High-Grade Glioma Cells Into Microfluidic Devices to Assess Electrical Interactions
Published on: November 17, 2021
相关概念视频
Ligand-gated Ion Channels
Three Subfamilies of Ligand-gated Ion Channels
Ligand-gated ion channels fall into three subfamilies. The 'Cys-loop' includes the nicotinic acetylcholine receptors, γ-aminobutyric acid (GABA), glycine, and 5-hydroxytryptamine receptors. The second one is the 'Pore-loop' channels that include the...
Ligand-Gated Ion Channel Receptor: Gating Mechanism
